8-K: Clene Inc. Secures $7.3 Million Subaward for ALS Expanded Access Program

Clene Inc. has entered into a subaward agreement with Columbia University for $7.3 million to support an Expanded Access Program for its CNM-Au8 treatment for ALS.

Summary

• Clene Inc. has finalized a subaward agreement with Columbia University, receiving up to $7.3 million for its Expanded Access Program (EAP) for CNM-Au8, a treatment for amyotrophic lateral sclerosis (ALS).
• This subaward is part of a larger $45.1 million grant from the National Institute of Health (NIH) awarded to Columbia University, with Clene as a collaborator.
• The $7.3 million covers expenses from September 25, 2023, to August 31, 2024, and will be disbursed to Clene based on monthly or quarterly invoices.
• Clene may receive up to $30.9 million in total subawards under the NIH grant, potentially extending to August 31, 2027, through future agreements.
• The subaward allows Clene to use its background intellectual property without granting licenses to Columbia or the U.S. Government.
• The agreement can be terminated by either party with 30 days' notice, or immediately if the NIH terminates the main grant.

Sentiment

Score: 8

Explanation: The document is positive due to the secured funding for a key program, with a clear path for future funding. The risks are manageable and typical for this type of agreement.

Positives

• The $7.3 million subaward provides significant funding for Clene's ALS treatment program.
• The potential for up to $30.9 million in total subawards offers long-term financial support.
• Clene retains full control over its background intellectual property.
• The agreement allows for monthly or quarterly reimbursement, ensuring consistent cash flow.

Negatives

• The subaward can be terminated with 30 days' notice by either party.
• The subaward is dependent on the continuation of the larger NIH grant.
• Disbursement of funds is contingent on the submission of invoices and may be subject to audit adjustments.

Risks

• The subaward is subject to termination if the NIH terminates the main grant.
• Future subawards are not guaranteed and will depend on further agreements.
• There is a risk of audit adjustments to payments made to Clene.
• The company is reliant on the success of the CNM-Au8 treatment for ALS.

Future Outlook

The company anticipates further subawards under the NIH grant, potentially extending to August 31, 2027, subject to future agreements and addendums.

Management Comments

• Robert Etherington, President and CEO of Clene Inc., signed the subaward agreement on behalf of the company.

Industry Context

This agreement highlights the ongoing efforts to develop treatments for ALS, a debilitating neurodegenerative disease, and the role of government funding in supporting such research. The collaboration between a biotech company, a university, and a specialty clinic is a common model in the pharmaceutical industry.

Comparison to Industry Standards

• The NIH grant and subaward are consistent with the trend of government funding for research into rare diseases like ALS.
• The $45.1 million NIH grant is a significant amount, comparable to other large grants awarded for similar research projects.
• The collaboration with Columbia University and Synapticure is a common practice in the biotech industry, leveraging expertise from different organizations.
• The use of an Expanded Access Program is a standard approach for providing experimental treatments to patients with serious conditions.

Stakeholder Impact

• Shareholders will likely view the subaward positively as it provides funding for a key program.
• Patients with ALS may benefit from the Expanded Access Program.
• Employees of Clene will be involved in the execution of the subaward.
• The collaboration strengthens Clene's relationship with Columbia University and Synapticure.

Next Steps

• Clene will submit monthly or quarterly invoices to Columbia University for reimbursement.
• Clene will continue to work with Columbia University and Synapticure on the Expanded Access Program.
• Clene will seek further subawards under the NIH grant through future agreements.

Key Dates

Keywords

Clene, ALS, CNM-Au8, Expanded Access Program, NIH Grant, Subaward, Columbia University, Amyotrophic Lateral Sclerosis, Intellectual Property, Funding